This cohort study compares sodium-glucose cotransporter 2 (SGLT2) inhibitors vs glucagonlike peptide-1 receptor agonists for dry eye disease in patients with type 2 diabetes in Taiwan. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.